A Phase 3, Long-Term Safety Study of Intravenous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 406 participants.

Also called NCT01628107

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 406 participants (enrolled count) (from the registry)
Sponsor
  • Pfizer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01628107
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Puerto Rico (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01628107. Allocation not applicable; no masking; primary purpose treatment. Start 2012-07-16 (actual); primary completion 2015-01-02 (actual). Results posted on 2018-07-19.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase 3, Long-Term Safety Study of Intravenous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin
Acronym
AiME - 03
Condition
Chronic Renal Failure Requiring Hemodialysis
Intervention (Biological)
Epoetin Hospira
Lead sponsor
Pfizer (class: industry)

Record details

Record id
cardio:ct-nct01628107
Content hash
fdd70c554a094da6be82c5712ba682a1277e97f02269d080c6f480cbf6773d24